Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ancer plus palliative radiation and continued ICI in NSCLC after ICI progression
jRCTs031250351Phase 2Recruiting
- Sponsor
- North East Japan Study Group
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Z-100 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by North East Japan Study Group. Primary endpoint: 1-year overall survival rate. Started Sep 2025; status: recruiting.
02
Drugs
Z-100
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031250351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250351.